Suppr超能文献

DWI 上的预处理 ASPECTS 可预测 rt-PA 后 3 个月的结局:SAMURAI rt-PA 登记研究。

Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.

机构信息

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

出版信息

Neurology. 2010 Aug 10;75(6):555-61. doi: 10.1212/WNL.0b013e3181eccf78.

Abstract

OBJECTIVE

To evaluate whether the pretreatment Alberta Stroke Programme Early CT Score (ASPECTS) assessed using diffusion-weighted imaging (DWI) predicts stroke outcomes at 3 months following IV recombinant tissue-type plasminogen activator (rt-PA) therapy.

METHODS

Stroke patients treated with rt-PA (0.6 mg/kg alteplase) in 10 stroke centers in Japan were retrospectively studied. ASPECTS was assessed on DWI just prior to rt-PA injection. The primary outcome was a modified Rankin Scale (mRS) score of 0-2 at 3 months. Secondary outcomes included death at 3 months and symptomatic intracerebral hemorrhage (sICH) within 36 hours.

RESULTS

For the 477 patients (316 men, 71 +/- 11 years old) enrolled, the median NIH Stroke Scale score was 13 (interquartile range 7-18.5), the median ASPECTS on DWI was 8 (7-10), and sICH was identified in 15 patients (3.1%). At 3 months, 245 (51.4%) had an mRS score of 0-2, and 29 (6.1%) had died. Patients with an mRS score of 0-2 had higher median ASPECTS (9; interquartile range 8-10) than other patients (8; 6-9, p < 0.001). Using receiver operating characteristic curves, the optimal cutoff ASPECTS to predict an mRS score of 0-2 was > or =7. On multivariate regression analysis, ASPECTS > or =7 was related to an mRS score of 0-2 (odds ratio 1.85; 95% confidence interval 1.07-3.24), ASPECTS < or =4 was related to death (3.61; 1.23-9.91), and ASPECTS < or =5 was related to sICH (4.74; 1.54-13.64).

CONCLUSION

ASPECTS on DWI was independently predictive of functional and vital outcomes at 3 months, as well as sICH within 36 hours, following rt-PA therapy for stroke patients.

摘要

目的

评估使用弥散加权成像(DWI)评估的预处理阿尔伯塔卒中计划早期 CT 评分(ASPECTS)是否能预测接受 IV 重组组织型纤溶酶原激活剂(rt-PA)治疗后 3 个月的卒中结局。

方法

回顾性研究了在日本 10 个卒中中心接受 rt-PA(0.6mg/kg 阿替普酶)治疗的卒中患者。在 rt-PA 注射前使用 DWI 评估 ASPECTS。主要结局为 3 个月时改良 Rankin 量表(mRS)评分 0-2。次要结局包括 3 个月时的死亡和 36 小时内的症状性颅内出血(sICH)。

结果

共纳入 477 例患者(316 例男性,71±11 岁),NIH 卒中量表评分中位数为 13(四分位距 7-18.5),DWI 上 ASPECTS 中位数为 8(7-10),15 例患者(3.1%)出现 sICH。3 个月时,245 例(51.4%)mRS 评分 0-2,29 例(6.1%)死亡。mRS 评分 0-2 的患者 ASPECTS 中位数较高(9;四分位距 8-10),而其他患者为 8(6-9,p<0.001)。使用受试者工作特征曲线,预测 mRS 评分 0-2 的最佳截断 ASPECTS 值为>或=7。多变量回归分析显示,ASPECTS>或=7 与 mRS 评分 0-2 相关(优势比 1.85;95%置信区间 1.07-3.24),ASPECTS<或=4 与死亡相关(3.61;1.23-9.91),ASPECTS<或=5 与 sICH 相关(4.74;1.54-13.64)。

结论

DWI 上的 ASPECTS 可独立预测 rt-PA 治疗卒中后 3 个月的功能和生存结局以及 36 小时内的 sICH。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验